Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04762602 · ClinicalTrials.gov registry record · Phase 1

A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations

A Phase 1 study, sponsored by Hutchmed.

Terminated
Registry status
Phase 1
Development phase
42
Enrollment target

NCT04762602 is a Phase 1 study that was terminated before completion, run by Hutchmed. The registered enrollment target is 42 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04762602, a Phase 1 study, was terminated before completion, sponsored by Hutchmed.

TERMINATED
Registry status
Phase 1
Development phase
42 participants
Enrollment target

Study Summary

An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in advanced or metastatic solid tumors with IDH mutation.

Interventions

  • DRUG HMPL-306

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2021-02-28
Est. Completion 2025-02-27
Phase Phase 1

Sponsor

Hutchmed

17 total trials

What the Registry Record Tells You About NCT04762602

The ClinicalTrials.gov registry entry for NCT04762602 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hutchmed, which has 17 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which HMPL-306 is the first listed.

NCT04762602 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04762602 about?

NCT04762602 is a clinical study titled "A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations". An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in advanced or metastatic solid tumors with IDH mutation.

What is the current status of trial NCT04762602?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2021-02-28. Estimated completion is 2025-02-27.

What interventions are being tested in trial NCT04762602?

The interventions under investigation include: HMPL-306 (DRUG).

Who is sponsoring clinical trial NCT04762602?

This trial is sponsored by Hutchmed, which has 17 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.